Report: Current Stock Reports

Achievement of the first milestone under licence agreement with Exelixis Inc.
January 26, 2023

Announcement of the NDS on registration of series J shares with the NDS
January 25, 2023

Publication dates for periodic reports in 2023
January 25, 2023

Notification from TFI Allianz Polska S.A. of a change in its share in the total number of votes in the Company
January 25, 2023

Admission and introduction of the series J shares of the Company to trading on the regulated market of the WSE
January 20, 2023

Conditional registration of the series J shares of the Company with the National Depository for Securities
January 20, 2023

Notification from a shareholder of a change in its share in the total number of votes in the Company
January 19, 2023

Notification from a shareholder of a change in his share in the total number of votes in the Company
January 18, 2023

Registration of amendment of the Company’s Articles of Association concerning share capital
January 18, 2023

Notification from PTE Allianz Polska S.A. of a change in its share in the total number of votes in the Company
January 9, 2023

Notification from a person discharging managerial responsibilities in the Company due to series J shares allotment – Article 19 of MAR
December 22, 2022

Notification from a person closely related to a person discharging managerial responsibilities in the Company due to series J shares allotment – Article 19 of MAR
December 22, 2022

Summary of the subscription of ordinary bearer series J shares
December 22, 2022

Allotment of series J shares
December 22, 2022

Determination of the final issue price of series J shares and the final number of series J shares that will be offered in the public offering
December 15, 2022

Ryvu Therapeutics presents Clinical and Translational Data of RVU120 and SEL24 (MEN1703) at the 2022 American Society of Hematology (ASH) Annual Meeting
December 11, 2022

Approval of the prospectus of the Company
December 7, 2022

Decision to conduct public offering of J series shares in December 2022
December 2, 2022

Disclosure of delayed confidential information regarding the start of negotiations and the non-binding determination of the key terms of a potential collaboration
November 30, 2022

Execution of an exclusive Research Collaboration Option and Exclusive License Agreement and Equity Investment Agreement with BioNTech SE
November 30, 2022